Topical Hyaluronic Acid and Recurrent Aphthous Stomatitis.

Cairo University34 enrolled

Overview

This study was conducted to estimate the hypothesis that the topical hyaluronic acid mouthwash have no role in the treatment of recurrent aphthous stomatitis

Recurrent aphthous stomatitis (RAS) is a common and widely recognized disorder involving the oral mucosa. It occurs typically as a single or multiple well-defined painful self-limiting ulcerative lesions influencing the nonkeratinized oral mucous membrane surrounded by red halo. The prevalence of RAS is up to 25% in the world population, with recurrence rate of 50% every 3 mouths. The exact cause of RAS is uncertain, and accordingly numerous components are as yet being implicated such as genetic, hormonal, traumatic, nutritional, allergic, immunological, and psychological factors.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Recurrent Aphthous Stomatitis

Interventions

Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwashDRUG

Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: The inclusion criteria were as follows: * Age 18-30 years. * Minimum of 2 years of RAS history, with active ulcer less than 48 hours of recurrent aphthous stomatitis. Exclusion Criteria: * known history of hypersensitivities to Chlorhexidine or hyaluronic acid. * Use of any medication as a treatment for the present active ulcer. * Smoking and presence of systemic diseases such as Behçet disease, anemia, Crohn's disease, ulcerative colitis, acquired immune deficiency syndrome, and liver or kidney disease. * Pregnant or breast-feeding women. * Stomach ulcer, duodenal ulcer, and inflammation of the stomach or the esophagus. * Treatment with systemic nonsteroidal anti-inflammatory drugs, systemic steroids or other immune modulatory agents, oral antihistamines, or systemic antibiotics in the previous 3 months.

Locations (1)

Faculty of Dentistry, Cairo University

Cairo, Egypt

Outcomes

Primary Outcomes

Pain score

Pain assessment scale, visual analog scale (VAS) comprising of a 10-cm straight line among ends, with 0 representing no pain (better outcome) and 10 for intolerable pain (worse outcome) after irritation of the ulcer with the periodontal probe.

Time frame: one week

Secondary Outcomes

Ulcer size

The ulcer size was evaluated by determining the distance between two opposed boundaries of the ulcer edge, using a periodontal probe in millimeters.Score for clinical improvement of the sign where high values indicate worse outcome but low values indicate better outcome.

Time frame: one week

Duration of healing

period of the ulceration for complete healing

Time frame: one week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.